Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University Medical School, UK.
Nat Rev Rheumatol. 2011 Aug 2;7(9):507-16. doi: 10.1038/nrrheum.2011.106.
Biologic therapies have been licensed to treat rheumatic diseases for more than a decade. In parallel, they have gained acceptance in a variety of non-rheumatic diseases, where their impact has been no less revolutionary. In this Review, we examine the application of biologics in a number of non-rheumatic autoimmune and inflammatory disorders-psoriasis, inflammatory bowel disease, uveitis, asthma, diabetes, congestive cardiac failure and multiple sclerosis. In particular, we have sought information, or lessons, that could influence their application in rheumatic diseases. For example, we highlight the potential to stratify asthma into groups that might require different targeted approaches, and focus on some of the less common adverse events associated with biologic therapies in multiple sclerosis. Similarly, we examine type 1 diabetes mellitus in the context of potential therapeutic induction of immune tolerance. Working collaboratively, across specialties, there is significant synergy to be gained in regard to understanding how biologic therapies work, how best to use them, and the adverse effects we should be conscious of.
生物制剂在治疗风湿性疾病方面已有十余年的应用历史。与此同时，它们在多种非风湿性疾病中也得到了认可，其影响同样具有革命性。在这篇综述中，我们研究了生物制剂在多种非风湿性自身免疫性和炎症性疾病（如银屑病、炎症性肠病、葡萄膜炎、哮喘、糖尿病、充血性心力衰竭和多发性硬化症）中的应用。特别是，我们寻求了可能影响其在风湿性疾病中应用的信息或经验。例如，我们强调了将哮喘分层为可能需要不同靶向治疗方法的可能性，并关注了多发性硬化症中与生物治疗相关的一些不太常见的不良反应。同样，我们也在探讨 1 型糖尿病的潜在治疗性免疫耐受的问题。通过跨专业合作，可以在理解生物治疗的作用机制、如何最佳使用它们以及我们应该注意的不良反应等方面获得显著的协同效应。
